Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus

Christos Papaneophytou; Andria Nicolaou; Myrtani Pieri; Vicky Nicolaidou; Eleftheria Galatou; Yiannis Sarigiannis; Markella Pantelidou; Pavlos Panayi; Theklios Thoma; Antonia Stavraki; Xenia Argyrou; Tasos Kalogiannis; Kyriacos Yiannoukas; Christos C Petrou; Kyriacos Felekkis

doi:10.1371/journal.pone.0269885

. 2022 Jun 13;17(6):e0269885. doi: 10.1371/journal.pone.0269885

Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus

Christos Papaneophytou ¹, Andria Nicolaou ², Myrtani Pieri ¹, Vicky Nicolaidou ¹, Eleftheria Galatou ¹, Yiannis Sarigiannis ¹, Markella Pantelidou ², Pavlos Panayi ², Theklios Thoma ², Antonia Stavraki ², Xenia Argyrou ², Tasos Kalogiannis ², Kyriacos Yiannoukas ², Christos C Petrou ¹, Kyriacos Felekkis ^1,^*

Editor: Tian Wang³

PMCID: PMC9191710 PMID: 35696396

Abstract

Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein were higher in individuals with evidence of prior infection who received at least one dose of either an mRNA-based vaccine (Comirnaty BNT162b2/Pfizer-BioNTech or Spikevax mRNA-1273/Moderna) or an adenoviral-based vaccine (Vaxzervia ChAdOx1 nCoV-19 /Oxford-Astra Zeneca) (n = 39) compared to i) unvaccinated individuals with evidence of prior infection with SARS-CoV-2 (n = 109) and ii) individuals without evidence of prior infection with SARS-CoV-2 who received one or two doses of one of the aforementioned vaccines (n = 342). Our analysis also revealed that regardless of the vaccine technology (mRNA-based and adenoviral vector-based) two doses achieved high anti- SARS-CoV-2 IgG responses. Our results indicate that vaccine-induced responses lead to higher levels of IgG antibodies compared to those produced following infection with the virus. Additionally, in agreement with previous studies, our results suggest that among individuals previously infected with SARS-CoV-2, even a single dose of a vaccine is adequate to elicit high levels of antibody response.

Introduction

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes COVID-19 continues to spread worldwide as a severe ongoing pandemic. Immunity to SARS-CoV-2, induced either through natural infection or vaccination, has been demonstrated to afford a degree of protection against reinfection and transmission of the virus and/or reduce the risk of clinically significant outcomes [1]. Antibodies against SARS-CoV-2 are an essential part of immunity against the virus, as an appropriate neutralizing response can efficiently block virions from successfully infecting Angiotensin-converting enzyme 2 (ACE-2) receptor-expressing cells. Understanding the humoral immune response and analyzing the antibody profiles induced against SARS-CoV-2 can guide public health measures and control strategies. However, antibody response against the SARS-CoV-2 is still a subject of debate and must be addressed carefully [2]. The protective role of antibodies against the virus and its variants remains unknown. However, such antibodies usually demonstrate a sufficient correlation of antiviral immunity, and anti–receptor-binding domain antibody levels correspond to plasma viral neutralizing activity [3].

The SARS-CoV-2 infection produces early detectable humoral immune responses in most patients, leading to the development of neutralizing antibodies (NAbs) in the vast majority of cases [4–7]. However, the duration, magnitude, and protective capacity of the humoral immune response remain elusive to date [8]. Seroprevalence has been reported to be low in the general population and varied among countries and territories. In addition, recent studies have reported a decline in neutralization titer with time for up to 8 months after SARS-CoV-2 infection [9–11]. Other studies have shown the induction of neutralizing and protective anti-SARS-CoV-2 antibodies after infection, which reduced the risk of reinfection for the following 13 months [12]. However, the long-term time course of the antibody response in COVID-19 disease is not yet fully determined. Some studies show a significant decrease in antibody concentrations within 3–4 months from the onset of symptoms [3, 13, 14]. Other reports find constant or only slightly decreased levels, starting from 4 months and up to 10 months from symptom onset [4–7], even when specific neutralizing antibodies [8] were measured. In particular, the time course of the antibody response seems variable, also according to the method used [7, 9]. On the other hand, antibodies seem to persist through 4–6 months in vaccinated individuals [10, 11].

Several SARS-CoV-2 vaccines have been developed and the European Medicines Agency (EMA), has utilised the rolling review regulatory tool to speed up the assessment process during a public health emergency. To date, EMA has granted five conditional approvals for vaccines that met a positive benefit-risk balance: BNT162b2 (Comirnaty, Pfizer/BioNTech), mRNA-1273 (Spikevax Moderna), ChAdOx1-S (Vaxzevria, AstraZeneca and the University of Oxford Vaxzevria), Ad26.COV2-S (Jahnsen—Johnson and Johnson), [15] and NVX-CoV2373 (Nuvaxovid, Novavax) [16]. These vaccines offer protection against SARS-CoV-2 by generating immune responses against the spike antigen of the virus. An ideal SARS-CoV-2 vaccine should prevent infection and protect from severe disease in all vaccinated populations, as well as elicit long-term memory immune responses after a minimal number of immunizations or booster doses [17]. On the other hand, regulatory agencies recommend that the primary endpoint should be how well a vaccine prevents laboratory-confirmed COVID-19 disease (symptomatic disease) of any severity and not whether a vaccine provides sterilizing immunity [18]. Although vaccines elicit a strong and protective immune response [19], the potency of such response relative to the response induced by infection is not well understood [20]. Moreover, the potency and durability of infection-induced SARS-CoV-2 immunity have crucial implications for reinfection and vaccine effectiveness [8].

A major question is whether vaccine-induced responses may be more durable, in terms of long-term protection, than those following infection [1]. Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting protection against reinfection and durability of vaccine protection [12]. Naturally, antibody profiles and dynamics vary depending on the Ig isotype of interest [21]. However, evidence has also been gathered indicating that there are dissimilar profiles of antibody kinetics depending on the antigen of interest, and consequently, natural antibody levels vary significantly and cannot be characterized as a whole [2]. It should be noted that the humoral response (i.e., antibodies) is not the only protective response against SARS-CoV-2 and other infections, and that cell-mediated immunity (i.e. T cells) may be maintained despite putative lack of detection in serum antibody levels [22].

Although it is still not clear whether antibodies against SARS-CoV-2 correlate with protective immunity, a study of SARS-CoV-2 antibodies among residents of certain geographical regions can aid in the estimation of the immunological protection against subsequent infection (see [11] and references cited therein). Furthermore, knowledge of the magnitude, timing, and longevity of antibody responses after SARS-CoV-2 infection is vital for understanding the role that antibodies might play in disease clearance and protection from reinfection and/or severe disease. Finally, as huge emphasis has been placed on antibody reactivity assays to determine seroprevalence against SARS-CoV-2 in the community to estimate infection rates, it is vital to understand immune responses after infection to define parameters in which antibody tests can provide meaningful data in the absence of PCR testing in population studies [23].

Even though the epidemic of COVID-19 in Cyprus started in Feb 2020, no seroprevalence data are available thus far. Furthermore, on 28^th December 2020, Cyprus began its national vaccination program with the Comirnaty vaccine followed by the approval of Spikevax and Vaxzervia vaccines. The current study has assessed the levels of SARS-CoV-2 antibodies in the general population of Cyprus. Specifically, we compared antibody levels among three groups of participants: i) vaccinated without evidence of previous infection, ii) unvaccinated with evidence of previous infection, and iii) vaccinated with evidence of previous infection. Blood samples were analyzed by enzyme-linked immunosorbent assay (ELISA) to detect anti–SARS-CoV-2 spike receptor-binding domain IgG antibodies.

Methods

Population

In this nationwide study, we enrolled 702 individuals from four cities (Nicosia, Limassol, Larnaca, and Paphos) in Cyprus from May to November 2021. Demographic data, including age, gender, place of residence, and occupation of each participant, were collected during recruitment. The study has been approved by the Cyprus National Bioethics Committee (EEBK/EΠ/2021/06). All individuals provided written consent to participate. In detail, blood samples were obtained aseptically from each participant at Yiannoukas Medical Laboratories/Bioiatriki Group throughout different locations in Cyprus. Participants visited Yiannoukas Medical Laboratories/Bioiatriki Group to provide blood for analysis for a routine check-up or other tests prescribed by their physicians. These individuals were informed about the study and its aims and asked if they were willing to donate an additional 5–9 mL of blood specifically for this study. Individuals that agreed were given the consent form to sign and also completed a short questionnaire requesting demographic data as well as whether the participant had ever tested positive for COVID-19 with either an antigen rapid test and/or an RT-qPCR test for SARS-CoV-2 or had received vaccination against COVID-19. Furthermore, only participants with a negative antigen rapid test and/or an RT-qPCR test for SARS-CoV-2 at the time of blood collection were eligible to enroll in this study.

Laboratory testing

Blood collection, handling, and storage

Five (5) to nine (9) mL of whole blood were collected from volunteers using needles of diameter >23 gauge to prevent hemolysis and were immediately transferred into commercially available plasma (clot activator) tubes. Each tube was labeled with a unique code. Tubes were inverted carefully 10 times to mix blood and anticoagulant and stored at 4^οC until centrifugation according to the rules proposed by the Standard Operating Procedures Internal Working Group (SOPIWG)/ Early Detection Research Network (EDRN) for specimen collection (including blood samples) [24]. To separate the plasma from cells, samples were centrifuged at 1500g for 20 min. Following centrifugation, the plasma was transferred into clean tubes using a sterile serological pipette. Samples were then maintained at 2–8°C until further processing.

Antibodies measurement

Specific anti-SARS-CoV-2-IgG levels were determined by the SIEMENS Dimension EXL system which employs a chemiluminescent immunoassay based on Luminescent oxygen channeling assay (LOCI) technology. The LOCI reagents include two synthetic bead reagents (Sensibeads and Chemibeads) and a biotinylated anti-human IgG antibody. Sensibeads are coated with streptavidin and contain photosensitizer. Chemibeads are coated with an anti-‑ Fluorescein isothiocyanate (FITC) antibody and contain chemiluminescent dye. Furthermore, the anti-FITC antibody-coated-Chemibeads are pre-decorated with fluoresceinated S1 receptor-binding domain (RBD) antigen of the spike protein of the SARS-CoV-2 virus. All components for the detection of anti-IgG against SARS-CoV-2 including the fluoresceinated S1 receptor-binding RBD antigen were included in the Dimension Vista SARS CoV 2 IgG (COV2G) assay (Siemens Healthcare Diagnostics Inc., Erlangen, Germany, Cat #K7771

11417771). The sample is incubated with Chemibeads for 1 minute and subsequently, the biotinylated antibody is added to form bead-CoV-2 antigen-biotinylated antibody sandwiches. After the completion of incubation, Sensibeads are added to bind to the biotin to form bead-pair immunocomplexes. Illumination of the complex at 680nm generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal was measured at 612nm and was proportional to IgG concertation in the sample. IgG levels were determined by the semiquantitative mode of the SIEMENS Dimension EXL system using a 5-level LOGIT calibration curve and the results were presented as relative (Ind) Units. The Dimension EXL system cutoff analyte value was 1000 relative Units and it was used to identify IgG positive samples. The sensitivity of the method (for samples obtained ≥ 14 days post-infection with SARS-CoV-2) was 100% (95% CI, 95.9–100%) and the specificity was 100% (95% CI, 95.8–100%).

Statistical analysis

Continuous variables with normal distribution were expressed as means ± standard deviation (SD) and categorical variables as counts and percentages). The normal distribution of continuous data was analyzed with the D’Agostino & Pearson omnibus normality test. Antibody levels were log-transformed before all statistical processes. IgG levels were not normally distributed, and thus are presented as median and interquartile ranges (IQR). We used the Mann-Whitney U- test and the Pearson′s Chi-square test to compare the IgG levels between groups. The linear relationship of IgG responses with the age of participants was carried out using Spearman’s correlation coefficient. Correlations were classified as very weak (correlation coefficient (r) < 0.20), weak (r = 0.20–0.39), moderate (r = 0.40–0.59), strong (r = 0.60–0.79), or very strong (r > 0.80). Statistical significance was set at p<0.05. Statistical analysis was performed using GraphPad Prism (v.8.2, GraphPad Software Inc., San Diego, CA, USA).

Results

Demographics and vaccination coverage

A total of 702 individuals participated in this study. Descriptive data for the study population are summarized in Table 1. The median (IQR) age was 43 years (33–59), 332 participants (47.3%) were men and 370 (52.7%) participants were women. Overall, 148 (21.1%) participants with a SARS-CoV-2 positive PCR-test or a positive nose/throat swab rapid test were considered to have previously been infected with SARS-CoV-2 regardless of whether they had reported previous symptoms, while 39 out of the 148 had received one or two doses of a licensed vaccine. From a total of 554 participants without evidence of previous infection, 339 had received either one or two doses of a licensed vaccine, 2 participants had received 3 doses of Pfizer/BioNTech and 1 participant had received 3 doses of the Moderna vaccine. Based on these definitions, we initially categorized participants into three groups as follows: i) vaccinated without evidence of prior infection (n = 342); ii) unvaccinated with evidence of prior infection (n = 109), and iii) vaccinated with evidence of prior infection (n = 39). Unvaccinated participants without evidence of prior infection (n = 212) were used as the control group. We also categorized participants into three age groups namely the 18–45 years of age (n = 385), 46–65 years of age (n = 222), and > 66 years of age (n = 95).

Table 1. Characteristics of the 702 participants.

Variable	All participants (n = 702)	No prior infection		Prior infection
		Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	p-value¹
		(n = 212)	(n = 342)	(109)	(n = 39)	p-value¹
Age, median (IQR)	43 (33–59)	38 (30–51)	49 (36–63)	40 (31–55)	45 (33–58)	<0.0001
Age Range
18–45, n (%)	385 (54.8)	140 (66.0)	158 (46.2)	66 (60.6)	21 (53.8)	<0.0001
46–65, n (%)	222 (31.7)	58 (27.4)	114 (33.3)	35 (32.1)	15 (38.5)
>66, n (%)	95 (13.5)	14 (6.6)	70 (20.5)	8 (7.3)	3 (7.7)
Gender
Male, n (%)	332 (47.3)	102 (48.1)	160 (46.8)	48 (44.0)	22 (56.4)	>0.05
Female, n (%)	370 (52.7)	110 (51.9)	182 (53.2)	61 (56.0)	17 (43.6)

Open in a new tab

Data are presented as median (IQR) or n (%)

¹ Difference among all types. Differences in measurement data among the four groups were compared with the Kruskal Wallis test followed by Dunn’s multiple comparisons test or Chi-squared test

Table 2 summarizes the vaccination coverage in terms of vaccine type and the number of doses in individuals with or without evidence of prior infection with SARS-CoV-2. It is shown that more than 63.5% of the participants (242 of 381) received one, two, or three doses of the Pfizer/BioNTech vaccine.

Table 2. Vaccination coverage in terms of vaccine type and number of doses given.

Vaccine	No prior infection (n = 342)			Prior infection (n = 39)
Vaccine	One dose (n = 78)	Two doses (n = 261)	Three doses (n = 3)	One dose (n = 25)	Two doses (n = 14)
Oxford Astra Zeneca	33	32	0	9	4
Pfizer-BioNTech	25	191	2	6	18
Moderna	10	38	1	0	2
Johnson & Johnson	10	-	-	-	-

Open in a new tab

Antibodies against SARS-CoV-2 increased following vaccination or infection as illustrated in Fig 1, while the levels of specific anti-spike IgG were significantly higher (p<0.0001) in all three groups compared to the control group (Fig 1). Specifically, without evidence of prior infection, anti-spike IgG antibodies were detected after vaccination in 312 of 342 (91.2%) participants. In the unvaccinated group with evidence of prior infection, antibodies were detected in 84 of 109 (77.1%) participants. Interestingly, in the vaccinated group with evidence of prior infection anti-spike IgG antibodies were detected in 100% of participants. Furthermore, this group (vaccinated with evidence of prior infection) also had the highest virus-specific IgG antibody levels detected as illustrated in Fig 1. Interestingly, the levels of specific anti-spike IgG were significantly higher (p<0.0001) in the vaccinated group without evidence of previous infection (n = 342) compared to the unvaccinated group with evidence of previous infection (n = 109). There was no statistical difference in anti-spike IgG antibodies levels between men and women in all groups as resulted by the Mann Whitney U test (S1 Fig). Due to the small number, individuals who received the Johnson and Johnson vaccine or 3 doses of either the Pfizer/BioNTech or the Moderna Vaccine (Table 2) were excluded from the subsequent analysis.

We then analyzed the antibody levels in participants without evidence of prior infection who received one dose or two doses of a vaccine in the three age groups (Fig 2A). After vaccination, anti-spike IgG antibodies were detected in 137 of 151 (90.7%) participants of the 18–45 years of age group. In the 46–65 years of age and >66 years of age groups, antibodies were detected in 104 of 110 (94.5%) and 65 of 68 (95.6%), respectively. Our analysis revealed that there were no statistically significant differences in specific anti-spike IgG levels among the three age groups (Fig 2A).

We also compared the levels of vaccine-elicited IgG after the administration of one and two doses of the same vaccine (Fig 2B). There was no statistically significant difference in anti-spike IgG levels between one dose and two doses of the Oxford-Astra Zeneca. Anti-spike IgG levels were significantly increased (p<0.05) following the second dose of the Moderna vaccine. Administration of a second dose of the Pfizer/BioNTech vaccine also resulted in the production of higher levels of IgG antibodies compared to the first dose, but these differences did not reach statistical significance (p>0.05). We then compared the levels of vaccine-elicited anti-spike IgG between the two different vaccine technologies, i.e., after the administration of i) one dose and ii) two doses of either an adenoviral-based vaccine (Oxford-Astra Zeneca) or an mRNA-based vaccine (Moderna or Pfizer-BioNTech). There was no statistically significant difference (p>0.05) in IgG levels between the groups who received a single dose of i) the Oxford- Astra Zeneca (n = 33) or Moderna (n = 10) vaccine and ii) the Oxford- Astra Zeneca (n = 33) and the Pfizer-BioNTech (n = 25) vaccine. There was also no statistically significant difference (p>0.05) in IgG levels between the groups who received a single dose of the Pfizer-BioNTech or Moderna vaccine. Anti-Spike IgG levels were significantly higher (p<0.0001) after two doses of Moderna (n = 38) than after Astra-Zeneca (n = 32). Vaccination with two doses of Pfizer/BioNTech (n = 191) induced the production of significantly higher levels (p<0.0001) of IgG antibodies than those produced after administration of two doses of Astra-Zeneca. However, there was no statistically significant difference (p>0.05) in the levels of anti-Spike IgG antibodies between the groups vaccinated with two doses of the Moderna or two doses of Pfizer-BioNTech (Fig 2B).

Correlation of antibody levels post-vaccination with the age of the participants

Participants without evidence of prior infection who had received at least one dose of a vaccine were included in a subsequent analysis, to investigate associations between IgG levels and the age of participants regardless of the type/doses of vaccine given. The differences in vaccine response by age group are presented in Fig 3. Spearman’s r-test revealed that there was no correlation (p>0.05) between the anti-spike IgG levels and the age of participants in the 18–45 years (Fig 3A) and 46–65 years groups (Fig 3B), however, the levels of IgG in the >66 years of age group were negatively and weakly correlated (r = -0.2454; p<0.05) with the age of participants (Fig 3C).

Fig 3 — Correlation between IgG levels and the age of participants in three age groups namely 18–45 years (A), 46–65 years (B), and > 66years (C) was performed with Spearman’s r-test. Dotted lines: positive cut-off values.

Comparison between the levels of SARS-CoV-2 antibodies elicited by SARS-CoV-2 vaccination and infection

As aforementioned, an important question is whether vaccine-induced responses are more potent and durable than those measured following natural infection. However, in the case of SARS-CoV-2, the extent to which infection can protect against subsequent reinfection remains unclear. Thus, we then sought to compare the levels of specific anti-SARs-CoV-2 IgG between vaccinated individuals without evidence of a previous infection with unvaccinated individuals with evidence of previous infection in the three age groups (Fig 4). Our analysis revealed that the levels of anti-spike IgG antibodies in vaccinated participants without evidence of prior infection were significantly higher compared to unvaccinated participants with evidence of prior infection in the 18–45 (p<0.0001) and 46–65 (p<0.01) age groups. However, there was no statistically significant difference (p>0.05) between the vaccine-elicited and infection-elicited antibodies in the >66 years of age group. Moreover, antibody responses in younger unvaccinated participants (18–45 years of age) with evidence of prior infection were lower compared to older participants (46–65 and >66 years of age group), but these differences did not reach statistical significance (p>0.05).

Fig 4 — Dot plots show the levels of anti-spike IgG in individuals without evidence of prior infection (NPI/V) who received one dose or two doses of a vaccine and unvaccinated individuals with evidence of prior infection (PI/U). The Mann-Whitney U-test was employed to compare the IgG levels in age groups. Statistically significant differences are indicated with asterisks: **p<0.01, ****p<0.0001, ns: non-significant. Horizontal bars indicate median values.

Moreover, in those without evidence of prior infection who received at least one dose of a vaccine, there was no statistically significant difference in anti-spike IgG antibodies levels between men and women in all age groups as resulted by the Mann Whitney U-test (S2 Fig). Finally, in unvaccinated individuals with evidence of prior infection, there was no statistically significant difference in IgG levels between men and women in all age groups as resulted by the Mann Whitney U-test (S3 Fig).

Time course of anti-spike IgG antibodies after vaccination with one dose

The time courses of the anti-spike IgG levels in individuals without evidence of previous infection who received one dose of a licensed vaccine are illustrated in Fig 5(A)–5(C). An increase in IgG levels was observed approximately 10 days post-vaccination regardless of the vaccine type (Fig 5A). Vaccinated individuals who had received one dose of an mRNA-based vaccine (Moderna or Pfizer/BioNTech) developed antibodies 10 days post-vaccination (Fig 5B), while high IgG titers were detected in individuals who received one dose of the Astra-Zeneca Vaccine (Fig 5C).

Fig 5 — A) Regardless of the vaccine type. B) mRNA-based vaccine (Moderna or Pfizer/BioNTech). C) Adenoviral-based vaccine (Oxford-Astra Zeneca).

Time course of anti-spike IgG antibodies after vaccination and natural infection

The time courses of the anti-spike IgG levels (counting begins on the day of the first dose) in individuals without evidence of previous infection, who received two doses of a licensed vaccine (regardless of the vaccine type), as well as vaccinated and unvaccinated individuals with evidence of prior infection, are illustrated in Fig 6.

Fig 6 — A) No prior infection and received two doses of a licensed vaccine. B) Prior infection and received one dose or two doses of a licensed vaccine. C) Prior infection without vaccination. For those who received two doses of a vaccine, the plots depict IgG levels from the date of the first vaccination.

Anti-spike IgG antibodies were detectable in 96% of participants with no prior infection who had received two doses of a vaccine, while antibody levels showed a slight decrease 120 days post-vaccination (Fig 6A). Interestingly, antibody levels persisted in individuals with prior evidence of infection who received one dose or two doses of a vaccine (Fig 6B). Finally, in those with evidence of prior infection who have not been vaccinated, IgG levels showed a decrease approximately 120 days post-infection reaching the background levels 240 post-infection (Fig 6C). Taken together, these results revealed that vaccination induces antibody levels significantly higher and likely more durable compared to those produced after infection with SARS-CoV-2.

Discussion

In this study, we assessed the immune response against SARS-CoV-2 in the general population in Cyprus between May and November 2021 by measuring the levels of specific anti-spike IgG antibodies and quantifying their levels over time. To the best of our knowledge, this is the first SARS-CoV-2 seroprevalence study carried out in Cyprus. The only other studies conducted in the Cypriot population examined the percentage of infected individuals in Cyprus who were able to produce antibodies against SARS-CoV-2 as well as the progression of SARS-CoV-2 antibody levels in SARS-CoV-2-infected individuals across time as a means of monitoring their antibody-mediated immunity after SARS-CoV-2 natural infection [25, 26].

A major question is whether there is a difference in the immunity conferred by natural SARS-CoV-2 infection vs. vaccination. Natural immunity is a feature of many viral infections, including, mumps, measles, and chickenpox, which induce remarkably stable neutralizing antibody responses [27]. The strength and duration of immunity after infection are key issues for ‘shield immunity’ [28], and for making informed decisions on how and when to ease physical distancing restrictions and other non-pharmacological interventions [29]. Previous studies have shown that circulating antibodies against SARS-CoV or MERS-CoV last for at least 1 year [30, 31]. Sustained IgG levels were maintained for more than 2 years after SARS-CoV infection [32, 33]. Antibody responses in individuals with laboratory-confirmed MERS-CoV infection lasted for at least 34 months after the outbreak [34]. However, in the case of SARS-CoV-2, the extent to which infection can protect against subsequent reinfection is unclear [20]. In addition, if there is indeed protection against reinfection, how long-lasting it is, is currently a topic of intense discussion [35]. Nevertheless, recent studies demonstrate that SARS-CoV-2 mRNA vaccines elicit long-lived antibody responses that partially recognize and protect against antigenically distinct SARS-CoV-2 variants [36]. Consistent with several previous studies [37, 38], our analysis revealed that vaccines elicit higher levels of antibodies against SARS-CoV-2 compared to those elicited after infection with the virus (Figs 1 and 4). For the duration of the current study, the prevalent variants circulating in Cyprus were the Alpha (B.1.1.7), Delta (B.1.617.2), and Delta plus (AY.4.2) [39]. Therefore, data obtained most probably involve this particular variant and cannot be generalized for other SARS-CoV-2 variants such as the more recent Omicron (B.1.1.529).

Among individuals without evidence of previous infection, all age groups achieved high antibody levels after vaccination with one or two doses of a vaccine (Fig 2A), while two doses of an mRNA-based vaccine induced higher antibody levels compared to those induced after the administration of single-dose (Fig 2B). Furthermore, antibody responses in younger participants (18–45 years of age) without evidence of prior infection who received at least one dose of a licensed vaccine were higher compared to older participants, however, these differences did not reach statistical significance (p>0.05) (Fig 2A).

Another important question is what happens when previously infected individuals are vaccinated. In this study, the highest levels of IgG were detected in the individuals with evidence of prior infection who had received one or two-dose of a vaccine. Recent studies by Stamatatos et al. [40] and Reynolds et al., [41] show that an impressive synergy occurs resulting from a combination of natural immunity and vaccine-generated immunity which is called “hybrid vigor immunity”. When natural immunity to SARS-CoV-2 is combined with vaccine-generated immunity, a larger-than-expected immune response arises and our findings seem to lend further support to this.

In agreement with previous studies, IgG levels were decreased with older age (Fig 3). In a recent study, Wei et al [42] reported a non-linear correlation of anti-spike IgG positivity with age, while seropositivity dropped faster in participants of >75 years of age. In addition, recent studies revealed that antibody responses to SARS-CoV-2 could be detected in most infected individuals approximately 2 weeks after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection [23]. Our analysis revealed that in the group without evidence of prior infection who received two doses of a vaccine, IgG levels showed a decrease 120–150 days post-vaccination (Fig 6A). A notable finding of this study was that antibody levels persisted in individuals with prior evidence of infection who received one dose or two doses of a vaccine (Fig 6B). However, in the unvaccinated group with evidence of prior infection, anti-IgG levels showed a sharp decrease approximately 100–120 days post-infection reaching the background levels after 240 days after infection (Fig 6C). The humoral response a few weeks after SARS-CoV-2 infection has been thoroughly described; some studies reported stable antibody levels within the first three months of recovery, whereas others showed a rapid decrease in convalescent patients [43]. Overall, our results suggest that two doses of vaccine lead to the induction of higher levels of long-lasting anti-spike IgG antibodies, while hybrid immunity to SARS-CoV-2 seems to be extremely potent. Recently Trougakos et al [44] demonstrated that natural infection promotes an earlier and more intense immune response compared to vaccination. However, the administration of a single dose of a vaccine to individuals previously infected with SARS-CoV-2 (hybrid immunity), or two doses in non-infected individuals, induces antibody levels significantly higher and likely more durable compared to natural infection.

Our study has some limitations. The limited information provided by participants of the study does not allow us to distinguish between differences in disease severity in the category of previously infected individuals. This category includes participants that could have been asymptomatic with just a positive molecular test, to have mild or severe disease. Additionally, this study was designed to only monitor for IgG antibodies and no other types such as IgA, etc. Additionally, utilizing more than one test/kit in future experiments can aid in determining the validity of the status of the samples for SARS-CoV-2 antibodies. It should be pointed out that determining antibody levels against SARS-CoV-2 could be useful in epidemiological studies, for estimating the spread of the infection and the lethality rate, in the serological diagnosis of individuals with mild or moderate symptoms, and those who are asymptomatic, in the first screening of convalescent patients for plasma collection and the monitoring of the antibody response of vaccinated subjects [36].

One strength of our study is that our tested population was drawn by random sampling, therefore minimizing the sampling bias on the estimation of seroprevalence in our population. Furthermore, measuring serum/plasma levels of virus-specific antibodies to SARS-CoV-2 could be used as an alternative method for detecting COVID-19 infection or as complementary tests, in addition to RT-PCR. Compared with the sampling methods required for RT-PCR, this serological assay reduces the risk of aerosol exposure, making it safer for medical staff to use. However, a limitation of antibody tests is that they require a longer window period after infection than RT-PCR [45]. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and the identification of asymptomatic infections [43].

Conclusions

Predicting the long-term potential for immune control of SARS-CoV-2 is challenging. Our results and those of others [40, 41] suggest that hybrid immunity to SARS-CoV-2 appears to be impressively potent. Our results also suggest that vaccine-induced responses are significantly more effective than natural immunity alone. Interestingly, and in consistence with previous studies, our results indicate that the vaccination of previously infected individuals drives a rapid and very potent recall of humoral immunity, even after a single vaccine dose.

Supporting information

S1 Fig. Comparison of anti-spike IgG antibody responses between men and women in the groups without or with evidence of prior infection.

Participants were not vaccinated (UnVac) or received at least one dose of a vaccine against SARS-CoV-2 (Vac). The number of participants (n) in each group is shown in parentheses. Mann-Whitney U-test was used for pairwise statistical analysis. There were no significant (ns) differences in anti-spike IgG antibody responses between men and women in all groups. Horizontal bars indicate median values. Dotted line: positive cut-off value.

(TIF)

Click here for additional data file.^{(576.8KB, tif)}

S2 Fig. Comparison of anti-spike IgG antibody responses between men and women in the age groups 18–45 years, 46–65 years, and >65 years following vaccination with at least one dose of a vaccine against SARS-CoV-2.

The number of participants (n) in each group is shown in parentheses. Mann-Whitney U-test was used for pairwise statistical analysis. There were no significant (ns) differences in anti-spike IgG antibody responses between men and women in all groups. Horizontal bars indicate median values. Dotted line: positive cut-off value.

(TIF)

Click here for additional data file.^{(461.2KB, tif)}

S3 Fig. Comparison of anti-spike IgG antibody responses between men and women in the age groups 18–45 years, 46–65 years, and >65 years after infection with SARS-CoV-2.

All participants were not vaccinated against SARS-CoV-2. The number of participants (n) in each group is shown in parentheses. Mann-Whitney U-test was used for pairwise statistical analysis. There were no significant (ns) differences in anti-spike IgG antibody responses between men and women in all groups. Horizontal bars indicate median values. Dotted line: positive cut-off value.

(TIF)

Click here for additional data file.^{(552KB, tif)}

Acknowledgments

We would like to express our special thanks to SIEMENS Healthcare which technical support throughout the study.

Data Availability

The data underlying the results presented in the study are available from (https://doi.org/10.5281/zenodo.5992410).

Funding Statement

The study was supported internally by the University of Nicosia and Yiannoukas Medical Laboratories/ Bioiatriki Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors did not receive any salary from the funders as part of this work.

References

1.Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi: 10.1038/s41591-021-01377-8 [DOI] [PubMed] [Google Scholar]
2.Chvatal-Medina M, Mendez-Cortina Y, Patino PJ, Velilla PA, Rugeles MT. Antibody responses in COVID-19: A review. Front Immunol. 2021;12:633184. doi: 10.3389/fimmu.2021.633184 [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–7. doi: 10.1056/NEJMc2025179 [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020;53(3):524–32.e4. doi: 10.1016/j.immuni.2020.07.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Liu LD, Lian C, Yeap LS, Meng FL. The development of neutralizing antibodies against SARS-CoV-2 and their common features. J Mol Cell Biol. 2020;12(12):980–6. doi: 10.1093/jmcb/mjaa070 [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. doi: 10.1126/sciimmunol.abe5511 [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52). doi: 10.1126/sciimmunol.abe0367 [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Altawalah H. Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines (Basel). 2021;9:8. doi: 10.3390/vaccines9080910 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan H-X, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12(1):1162. doi: 10.1038/s41467-021-21444-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–44. doi: 10.1038/s41586-021-03207-w [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Ristić M, Milosavljević B, Vapa S, Marković M, Petrović V. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. PLOS ONE. 2021;16(7):e0254516. doi: 10.1371/journal.pone.0254516 [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling M-J, et al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. Medrxiv. 2021: doi: 10.1101/2021.05.07.21256823%JmedRxiv [DOI] [Google Scholar]
13.Kutsuna S, Asai Y, Matsunaga A. Loss of anti-SARS-CoV-2 antibodies mild Covid-19. N Engl J Med. 2020;383(17):1695–6. doi: 10.1056/NEJMc2027051 [DOI] [PubMed] [Google Scholar]
14.Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–4. doi: 10.1038/s41591-020-0965-6 [DOI] [PubMed] [Google Scholar]
15.García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9(5):433. doi: 10.3390/vaccines9050433 [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2021: doi: 10.1056/NEJMoa2116185 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1):28. doi: 10.1038/s41541-021-00292-w [DOI] [PMC free article] [PubMed] [Google Scholar]
18.European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-studies-approval. Accessed 15 January 2022 [
19.Clark NM, Janaka SK, Hartman W, Stramer S, Goodhue E, Weiss J, et al. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection. bioRxiv. 2021: doi: 10.1101/2021.09.14.460394 [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020;50:101422. doi: 10.1016/j.smim.2020.101422 [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol. 2020;3(1):780. doi: 10.1038/s42003-020-01526-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020;20(10):581–2. doi: 10.1038/s41577-020-00436-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–607. doi: 10.1038/s41564-020-00813-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113–7. doi: 10.1021/pr800545q [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Krashias G, Deeba E, Constantinou A, Hadjiagapiou M, Koptides D, Richter J, et al. Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population. Microorganisms. 2022;10(1):85. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Mamais I, Malatras A, Papagregoriou G, Giallourou N, Kakouri AC, Karayiannis P, et al. Circulating IgG levels in SARS-CoV-2 convalescent individuals in Cyprus. J Clin Med. 2021;10(24):5882. doi: 10.3390/jcm10245882 [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–15. doi: 10.1056/NEJMoa066092 [DOI] [PubMed] [Google Scholar]
28.Weitz JS, Beckett SJ, Coenen AR, Demory D, Dominguez-Mirazo M, Dushoff J, et al. Modeling shield immunity to reduce COVID-19 epidemic spread. Nat Med. 2020;26(6):849–54. doi: 10.1038/s41591-020-0895-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Norheim OF. Protecting the population with immune individuals. Nat Med. 2020;26(6):823–4. doi: 10.1038/s41591-020-0896-2 [DOI] [PubMed] [Google Scholar]
30.Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–3. doi: 10.1056/NEJMc070348 [DOI] [PubMed] [Google Scholar]
31.Choe PG, Perera R, Park WB, Song KH, Bang JH, Kim ES, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017;23(7):1079–84. doi: 10.3201/eid2307.170310 [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Guo X, Guo Z, Duan C, Chen Z, Wang G, Lu Y, et al. Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers. Medrxiv. 2020:2020.02.12.20021386. doi: 10.1101/2020.02.12.20021386%J medRxiv. [DOI] [Google Scholar]
33.Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, Zhang L-Y, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–4. doi: 10.3201/eid1310.070576 [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824–6. doi: 10.3201/eid2210.160706 [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21(6):395–404. doi: 10.1038/s41577-021-00550-x [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Dittadi R, Seguso M, Bertoli I, Afshar H, Carraro P. Antibodies against SARS-CoV-2 time course in patients and vaccinated subjects: An evaluation of the harmonization of two different methods. Diagnostics (Basel). 2021;11(9):1709. doi: 10.3390/diagnostics11091709 [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595(7867):426–31. doi: 10.1038/s41586-021-03696-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci Transl Med. 2021;13(600):eabi9915. doi: 10.1126/scitranslmed.abi9915 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Cyprus Ministry of Health: https://www.pio.gov.cy/coronavirus/categories/press. Accessed 18 January 2022
40.Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372(6549):1413–8. doi: 10.1126/science.abg9175 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372(6549):1418–23. doi: 10.1126/science.abh1282 [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6(9):1140–9. doi: 10.1038/s41564-021-00947-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8. doi: 10.1038/s41591-020-0897-1 [DOI] [PubMed] [Google Scholar]
44.Trougakos IP, Terpos E, Zirou C, Sklirou AD, Apostolakou F, Gumeni S, et al. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine. 2021;19(1):208. doi: 10.1186/s12916-021-02090-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Nakano Y, Kurano M, Morita Y, Shimura T, Yokoyama R, Qian C, et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep. 2021;11(1):2776. doi: 10.1038/s41598-021-82428-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0269885.r001

Decision Letter 0

Tian Wang

27 Apr 2022

PONE-D-22-04892Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in CyprusPLOS ONE

Dear Dr. Felekkis,

Thank you for submitting your manuscript to PLOS ONE. While both reviewers consider the results of this study valuable and interesting for the field, they have raised a number of concerns (see the comments listed below). Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process, in particular, the concern on experimental details of IgG titration and antigen used for detection of IgG should be addressed.

Please submit your revised manuscript by Jun 09 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tian Wang, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Comments to the author:

In this manuscript, the authors used blood samples from 702 participants from four cities in Cyprus (Europe) to estimate the seroprevalence of SARS-CoV2 IgG antibody and to compare the antibody levels among three groups of participants including: i) vaccinated without evidence of the previous infection, ii) unvaccinated with evidence of the previous infection, and iii) vaccinated with evidence of the previous infection. The results from this study revealed that the highest response of virus-specific IgG antibodies were observed in individuals who were infected with SARS-CoV-2 and received at least one dose of a vaccine. The results also indicate that vaccine-induced responses lead to higher IgG antibodies response compared to those produced following infection with the virus.

I find the study noteworthy because 1) the data overall for SARS-CoV2 infection in Cyprus is limited, and 2) the study employed a large sample size and different groups which strengthens the study. Here are several points that need to be considered:

Major points:

- I would suggest analyzing some of the SARS-CoV2 IgG positive samples in the viral neutralization assay to determine the magnitude of neutralizing antibodies (NAbs).

- The manuscript lack samples from different time points. Therefore, I would suggest the authors include flow-up samples if that is possible for the durability of the IgG responses.

Minor points:

- The abstract section is poorly written. Therefore I would suggest the authors improve the abstract by summarizing/revising the current abstract.

- What are the methods used to determine the previous SARS-2. I encourage the author to state that in the methods section.

- Since the blood samples were collected in the anticoagulant tube, samples should be plasma not serum samples, I encourage the authors correct that in the method section.

- P6 and P7: in the methods section, subtitle laboratory testing, I suggest the authors to describe the assays in this section separately, for instance, ELISA should be in the separate subtitle with more details..……..etc.

- The specificity and sensitivity of the ELISA assay should be mentioned in the method section.

- Since the collected samples from participants visited the clinic for routine check-up or other tests, Are the patients have SARS-CoV2 acute symptoms? If so, are the samples tested for the IgM antibody? It would be nice if the authors include the IgM data since some samples maybe collected during the acute phase of infection.

- The authors should describe how they determine the antibody level somewhere in the manuscript. otherwise, the term lgG level should be changed to the IgG titer if they already checked the titer if not they should write IgG response.

- The IgG subclass need to be tested at least for the samples that show high IgG response.

- The study inclusion/exclusion criteria in general need further explanation for the reader. For example, were subjects with COVID-19 symptoms excluded? What tests were performed to exclude other common causes of COVID-19 disease-like symptoms?

- P20L456-457: The authors stated that their results also “suggest that vaccine-induced responses are significantly more effective than natural immunity alone” I think this statement needs to be discussed /explained in more detail in the discussion section.

- The discussion should describe the findings in a more concise manner.

In general, this work deals with an important topic and provides useful information to the reader. However, given all the above concerns, I believe this manuscript requires fixing the points before being accepted for publication.

Reviewer #2: In this study, the authors performed sera analysis of SARS-COV2 -IgG levels among unvaccinated, infected and vaccinated populations in Cyprus. Aging, vaccine type, Vaccine time course and natural infection have been used as parameters of comparison. The main conclusion of this study is that vaccine-induced higher IgG responses compared to SARS-COV2 infection. Overall, the manuscript is nicely written and the conclusions were supported by the results. The results are interesting to the field. There are a few concerns to be addressed:

1) Methods section: Information for the SARS-COV2 spike protein used for the detection of IgG responses is not clearly described, such as resource of the antigen, etc.

2) Methods section: it’s not clear how the IgG titers were determined. What’s the cutoff?

3) The abstract section needs to be more concise.

4) Line 354: please add “days” after “120”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1:

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Comments_PONE-D-22-04892_reviewer_04.04.22.pdf

Click here for additional data file.^{(85.2KB, pdf)}

PLoS One. 2022 Jun 13;17(6):e0269885. doi: 10.1371/journal.pone.0269885.r002

Author response to Decision Letter 0

4 May 2022

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Our revised manuscript meets PLOS ONE's style requirements including those for file naming.

2. Thank you for stating the following financial disclosure:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

The study was supported internally by the University of Nicosia and Yiannoukas Medical Laboratories/ Bioiatriki Group

b) State what role the funders took in the study. If the funders had no role in your study, please state:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

The authors did not receive any salary from the funders as part of this work.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

We have already provided the DOI to access our data (P.21, LL.481-482):

“Dataset are deposited in Zenodo and can be accessed through the following link: https://doi.org/10.5281/zenodo.5992410”

We remove the phrase “data not shown” and we are providing these results as supplementary figures (S1-S3).

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

The ethics statement appears only in the Methods section of the revised manuscript (P.6, LL. 136-137)

Reviewers' comments

Reviewer #1

Major points:

1. I would suggest analyzing some of the SARS-2 IgG positive samples in the viral neutralization assay to determine the magnitude of neutralizing antibodies (NAbs).

This is an interesting and valid pont. However, due to budget limitations we were not able to perform experiments to determine the magnitude of neutralizing antibodies (NAbs) in the recruited subjects.

2. The manuscript lacks samples from different time points. Therefore, I would suggest the authors include flow-up samples if that is possible for the durability of the IgG responses.

Indeed, it would be interesting to assess the durability of the IgG responses. However, this study did not include follow-up experiments. The approval we obtained from the Cyprus Bioethics Committee allowed us to collect samples from participants only one time.

Minor points:

1. The abstract section is poorly written. Therefore, I would suggest the authors improve the abstract by summarizing/revising the current abstract.

We thank the Reviewer for this valuable comment. We revised the abstract and reduced its length.

2. What are the methods used to determine the previous SARS-2. I encourage the author to state that in the methods section.

We thank the reviewer for this comment. The methods used (i.e., antigen rapid test or RT-qPCR test) are mentioned in the revised manuscript. P.6, LL.145-146.

3. Since the blood samples were collected in the anticoagulant tube, samples should be plasma not serum samples, I encourage the authors correct that in the method section.

The Reviewer is right. We replaced “serum” with “plasma” in the revised manuscript.

4. P6 and P7: in the methods section, subtitle laboratory testing, I suggest the authors to describe the assays in this section separately, for instance, ELISA should be in the separate subtitle with more details...…….etc.

This section has been corrected according to the Reviewer’s instructions.

5. The specificity and sensitivity of the ELISA assay should be mentioned in the method section.

The specificity and sensitivity of the ELISA assay are mentioned in the revised manuscript (P.8, LL.180-182).

“The sensitivity of the method (for samples obtained ≥ 14 days post-infection with SARS-CoV-2) was 100% (95% CI, 95.9-100%) and the specificity was 100% (95% CI, 95.8-100%).”

6. Since the collected samples from participants visited the clinic for routine check-up or other tests, Are the patients have SARS-CoV2 acute symptoms? If so, are the samples tested for the IgM antibody? It would be nice if the authors include the IgM data since some samples maybe collected during the acute phase of infection.

We agree with the Reviewer. However, in this study subjects with COVID-19 symptoms were excluded from this study and only individuals with a negative antigen rapid test and/or RT-qPCR test were eligible to participate in this study.

7. The authors should describe how they determine the antibody level somewhere in the manuscript. otherwise, the term lgG level should be changed to the IgG titer if they already checked the titer if not, they should write IgG response.

We thank the Reviewer for this comment. We added the following paragraph (PP.7-8, LL.175-180) in the revised manuscript to explain how we determined the antibody levels (in relative units):

“The resulting signal was measured at 612nm and was proportional to IgG concertation in the sample. IgG levels were determined by the semiquantitative mode of the SIEMENS Dimension EXL system using a 5-level LOGIT calibration curve and the results were presented as relative (Ind) Units. The Dimension EXL system cutoff analyte value was 1000 relative Units and it was used to identify IgG positive samples”.

8. The IgG subclass need to be tested at least for the samples that show high IgG response.

We thank the Reviewer for this interesting comment. Indeed, it would be interesting to test the IgG subclass in the samples containing high IgG levels. However, we were not able to perform these experiments due to budget limitations.

9. The study inclusion/exclusion criteria in general need further explanation for the reader. For example, were subjects with COVID-19 symptoms excluded? What tests were performed to exclude other common causes of COVID-19 disease-like symptoms?

Subjects with COVID-19 symptoms were excluded from this study and only individuals with a negative antigen rapid test and/or RT-qPCR test were eligible to participate in this study. We also mentioned this limitation in the revised manuscript (P.6, LL.146-148).

“Furthermore, only participants with a negative antigen rapid test and/or an RT-qPCR test for SARS-CoV-2 at the time of blood collection were eligible to enroll in this study.

10. P20, L456-457: The authors stated that their results also “suggest that vaccine-induced responses are significantly more effective than natural immunity alone” I think this statement needs to be discussed /explained in more detail in the discussion section.

This statement is extensively discussed in the discussion section (P18. LL.398-405) as follows:

“ However, in the case of SARS-CoV-2, the extent to which infection can protect against subsequent reinfection is unclear (20). In addition, if there is indeed protection against reinfection, how long-lasting it is, is currently a topic of intense discussion(35). Nevertheless, recent studies demonstrate that SARS-CoV-2 mRNA vaccines elicit long-lived antibody responses that partially recognize and protect against antigenically distinct SARS-CoV-2 variants (36). Consistent with several previous studies (37, 38), our analysis revealed that vaccines elicit higher levels of antibodies against SARS-CoV-2 compared to those elicited after infection with the virus (Fig 1 and 4).”

11. The discussion should describe the findings in a more concise manner.

We appreciate Reviewer’s comment. We feel that the above changes will make the description of the findings more concice. We strongly believe that if we further modify the content of the discussion session it would weaken our findings.

Thank you for your valuable comments and effort.

Reviewer #2:

In this study, the authors performed sera analysis of SARS-COV2 -IgG levels among unvaccinated, infected and vaccinated populations in Cyprus. Aging, vaccine type, Vaccine time course and natural infection have been used as parameters of comparison. The main conclusion of this study is that vaccine-induced higher IgG responses compared to SARS-COV2 infection. Overall, the manuscript is nicely written and the conclusions were supported by the results. The results are interesting to the field. There are a few concerns to be addressed:

1. Methods section: Information for the SARS-COV2 spike protein used for the detection of IgG responses is not clearly described, such as resource of the antigen, etc.

More information about the spike protein used for the detection of IgG responses has been added in the revised manuscript. (P.7, LL.165-170.)

“The LOCI reagents include two synthetic bead reagents (Sensibeads and Chemibeads) and a biotinylated mouse anti-human IgG antibody. Sensibeads are coated with streptavidin and contain photosensitizer. Chemibeads are coated with anti-‑ Fluorescein isothiocyanate (FITC) antibody and contain chemiluminescent dye. Furthermore, the anti-FITC antibody-coated-Chemibeads are pre-decorated with fluoresceinated S1 receptor-binding domain (RBD) antigen of the spike protein of SARS-CoV-2 virus.”

2. Methods section: it’s not clear how the IgG titers were determined. What’s the cutoff?

We thank the Reviewer for this comment. We added the following paragraph (PP.8, LL.175-170) in the revised manuscript to explain how we determined the antibody levels (in relative units):

3. The abstract section needs to be more concise.

We thank the Reviewer for this valuable comment. We revised the abstract and reduced its length.

4. Line 354: please add “days” after “120”

Corrected

Attachment

Submitted filename: PONE-D-22-04892_Response to Reviewers Comments - KF.docx

Click here for additional data file.^{(30.8KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0269885.r003

Decision Letter 1

Tian Wang

17 May 2022

PONE-D-22-04892R1Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in CyprusPLOS ONE

Dear Dr. Felekkis,

Thank you for submitting your revised manuscript to PLOS ONE. Although both reviewers felt the manuscript has been improved significantly, there are some remaining concerns to be addressed (see the comments below). Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

We look forward to receiving your revised manuscript.

Kind regards,

Tian Wang, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Reviewer #1: Comments to the author:

This work deals with an important topic and provides useful information to the reader. I believe the manuscript has been improved a lot.

Minor points:

- Some areas of the manuscript require significant proofreading and revision is needed to improve the quality of English for instance the abstract section has unclear sentences.

- Source of the reagents should be provided in the method section (antibody measurement section).

Reviewer #2: The authors have partially addressed my concerns. Here are the remaining concerns to be addressed:

1. Line 170: Please include the resource (company) where the fluoresceinated S1 receptor-binding RBD antigen was purchased, including the catalog #. If the antigen was made in house, please include the sequence information.

2. Line 29: please add “,” after this study, and change “plasma the” to “the plasma”.

3. Line 42: please change “humoral immunity” to “antibody responses”

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Attachment

Submitted filename: PONE-D-22-04892R1.pdf

Click here for additional data file.^{(46.5KB, pdf)}

PLoS One. 2022 Jun 13;17(6):e0269885. doi: 10.1371/journal.pone.0269885.r004

Author response to Decision Letter 1

22 May 2022

Reviewer #1:

Comments to the author:

This work deals with an important topic and provides useful information to the reader. I believe the manuscript has been improved a lot.

Minor points:

- Some areas of the manuscript require significant proofreading and revision is needed to improve the quality of English for instance the abstract section has unclear sentences.

The manuscript was reviewed and revised accordingly.

- Source of the reagents should be provided in the method section (antibody measurement section).

The source of reagents is provided in the revised manuscript (Siemens Healthcare Diagnostics Inc., Erlangen, Germany).

Reviewer #2:

The authors have partially addressed my concerns. Here are the remaining concerns to be addressed:

The following text was added to the manuscript to address reviewer’s comment

“All components for the detection of anti-IgG against SARS-CoV-2 including the fluoresceinated S1 receptor-binding RBD antigen were included in the Dimension Vista SARS CoV 2 IgG (COV2G) assay (Siemens Healthcare Diagnostics Inc., Erlangen, Germany, Cat #K7771

11417771)”

2. Line 29: please add “,” after this study, and change “plasma the” to “the plasma”.

Corrected

3. Line 42: please change “humoral immunity” to “antibody responses”

Corrected

Attachment

Submitted filename: PONE-D-22-04892R1_response to Reviewers comments 180522.docx

Click here for additional data file.^{(15.9KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0269885.r005

Decision Letter 2

Tian Wang

30 May 2022

Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus

PONE-D-22-04892R2

Dear Dr. Felekkis,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Tian Wang, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

PLoS One. doi: 10.1371/journal.pone.0269885.r006

Acceptance letter

Tian Wang

3 Jun 2022

PONE-D-22-04892R2

Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus

Dear Dr. Felekkis:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tian Wang

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. Comparison of anti-spike IgG antibody responses between men and women in the groups without or with evidence of prior infection.

(TIF)

Click here for additional data file.^{(576.8KB, tif)}

(TIF)

Click here for additional data file.^{(461.2KB, tif)}

S3 Fig. Comparison of anti-spike IgG antibody responses between men and women in the age groups 18–45 years, 46–65 years, and >65 years after infection with SARS-CoV-2.

(TIF)

Click here for additional data file.^{(552KB, tif)}

Attachment

Submitted filename: Comments_PONE-D-22-04892_reviewer_04.04.22.pdf

Click here for additional data file.^{(85.2KB, pdf)}

Attachment

Submitted filename: PONE-D-22-04892_Response to Reviewers Comments - KF.docx

Click here for additional data file.^{(30.8KB, docx)}

Attachment

Submitted filename: PONE-D-22-04892R1.pdf

Click here for additional data file.^{(46.5KB, pdf)}

Attachment

Submitted filename: PONE-D-22-04892R1_response to Reviewers comments 180522.docx

Click here for additional data file.^{(15.9KB, docx)}

Data Availability Statement

The data underlying the results presented in the study are available from (https://doi.org/10.5281/zenodo.5992410).

[pone.0269885.ref001] 1.Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi: 10.1038/s41591-021-01377-8 [DOI] [PubMed] [Google Scholar]

[pone.0269885.ref002] 2.Chvatal-Medina M, Mendez-Cortina Y, Patino PJ, Velilla PA, Rugeles MT. Antibody responses in COVID-19: A review. Front Immunol. 2021;12:633184. doi: 10.3389/fimmu.2021.633184 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref003] 3.Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–7. doi: 10.1056/NEJMc2025179 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref004] 4.Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020;53(3):524–32.e4. doi: 10.1016/j.immuni.2020.07.020 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref005] 5.Liu LD, Lian C, Yeap LS, Meng FL. The development of neutralizing antibodies against SARS-CoV-2 and their common features. J Mol Cell Biol. 2020;12(12):980–6. doi: 10.1093/jmcb/mjaa070 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref006] 6.Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. doi: 10.1126/sciimmunol.abe5511 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref007] 7.Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52). doi: 10.1126/sciimmunol.abe0367 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref008] 8.Altawalah H. Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines (Basel). 2021;9:8. doi: 10.3390/vaccines9080910 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref009] 9.Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan H-X, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12(1):1162. doi: 10.1038/s41467-021-21444-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref010] 10.Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–44. doi: 10.1038/s41586-021-03207-w [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref011] 11.Ristić M, Milosavljević B, Vapa S, Marković M, Petrović V. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. PLOS ONE. 2021;16(7):e0254516. doi: 10.1371/journal.pone.0254516 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref012] 12.Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling M-J, et al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. Medrxiv. 2021: doi: 10.1101/2021.05.07.21256823%JmedRxiv [DOI] [Google Scholar]

[pone.0269885.ref013] 13.Kutsuna S, Asai Y, Matsunaga A. Loss of anti-SARS-CoV-2 antibodies mild Covid-19. N Engl J Med. 2020;383(17):1695–6. doi: 10.1056/NEJMc2027051 [DOI] [PubMed] [Google Scholar]

[pone.0269885.ref014] 14.Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–4. doi: 10.1038/s41591-020-0965-6 [DOI] [PubMed] [Google Scholar]

[pone.0269885.ref015] 15.García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9(5):433. doi: 10.3390/vaccines9050433 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref016] 16.Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2021: doi: 10.1056/NEJMoa2116185 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref017] 17.Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1):28. doi: 10.1038/s41541-021-00292-w [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref018] 18.European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-studies-approval. Accessed 15 January 2022 [

[pone.0269885.ref019] 19.Clark NM, Janaka SK, Hartman W, Stramer S, Goodhue E, Weiss J, et al. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection. bioRxiv. 2021: doi: 10.1101/2021.09.14.460394 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref020] 20.Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020;50:101422. doi: 10.1016/j.smim.2020.101422 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref021] 21.Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol. 2020;3(1):780. doi: 10.1038/s42003-020-01526-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref022] 22.Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020;20(10):581–2. doi: 10.1038/s41577-020-00436-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref023] 23.Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–607. doi: 10.1038/s41564-020-00813-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref024] 24.Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113–7. doi: 10.1021/pr800545q [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref025] 25.Krashias G, Deeba E, Constantinou A, Hadjiagapiou M, Koptides D, Richter J, et al. Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population. Microorganisms. 2022;10(1):85. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref026] 26.Mamais I, Malatras A, Papagregoriou G, Giallourou N, Kakouri AC, Karayiannis P, et al. Circulating IgG levels in SARS-CoV-2 convalescent individuals in Cyprus. J Clin Med. 2021;10(24):5882. doi: 10.3390/jcm10245882 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref027] 27.Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–15. doi: 10.1056/NEJMoa066092 [DOI] [PubMed] [Google Scholar]

[pone.0269885.ref028] 28.Weitz JS, Beckett SJ, Coenen AR, Demory D, Dominguez-Mirazo M, Dushoff J, et al. Modeling shield immunity to reduce COVID-19 epidemic spread. Nat Med. 2020;26(6):849–54. doi: 10.1038/s41591-020-0895-3 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref029] 29.Norheim OF. Protecting the population with immune individuals. Nat Med. 2020;26(6):823–4. doi: 10.1038/s41591-020-0896-2 [DOI] [PubMed] [Google Scholar]

[pone.0269885.ref030] 30.Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–3. doi: 10.1056/NEJMc070348 [DOI] [PubMed] [Google Scholar]

[pone.0269885.ref031] 31.Choe PG, Perera R, Park WB, Song KH, Bang JH, Kim ES, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017;23(7):1079–84. doi: 10.3201/eid2307.170310 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref032] 32.Guo X, Guo Z, Duan C, Chen Z, Wang G, Lu Y, et al. Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers. Medrxiv. 2020:2020.02.12.20021386. doi: 10.1101/2020.02.12.20021386%J medRxiv. [DOI] [Google Scholar]

[pone.0269885.ref033] 33.Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, Zhang L-Y, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–4. doi: 10.3201/eid1310.070576 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref034] 34.Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824–6. doi: 10.3201/eid2210.160706 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref035] 35.Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21(6):395–404. doi: 10.1038/s41577-021-00550-x [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref036] 36.Dittadi R, Seguso M, Bertoli I, Afshar H, Carraro P. Antibodies against SARS-CoV-2 time course in patients and vaccinated subjects: An evaluation of the harmonization of two different methods. Diagnostics (Basel). 2021;11(9):1709. doi: 10.3390/diagnostics11091709 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref037] 37.Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595(7867):426–31. doi: 10.1038/s41586-021-03696-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref038] 38.Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci Transl Med. 2021;13(600):eabi9915. doi: 10.1126/scitranslmed.abi9915 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref039] 39.Cyprus Ministry of Health: https://www.pio.gov.cy/coronavirus/categories/press. Accessed 18 January 2022

[pone.0269885.ref040] 40.Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372(6549):1413–8. doi: 10.1126/science.abg9175 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref041] 41.Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372(6549):1418–23. doi: 10.1126/science.abh1282 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref042] 42.Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6(9):1140–9. doi: 10.1038/s41564-021-00947-3 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref043] 43.Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8. doi: 10.1038/s41591-020-0897-1 [DOI] [PubMed] [Google Scholar]

[pone.0269885.ref044] 44.Trougakos IP, Terpos E, Zirou C, Sklirou AD, Apostolakou F, Gumeni S, et al. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine. 2021;19(1):208. doi: 10.1186/s12916-021-02090-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0269885.ref045] 45.Nakano Y, Kurano M, Morita Y, Shimura T, Yokoyama R, Qian C, et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep. 2021;11(1):2776. doi: 10.1038/s41598-021-82428-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus

Christos Papaneophytou

Andria Nicolaou

Myrtani Pieri

Vicky Nicolaidou

Eleftheria Galatou

Yiannis Sarigiannis

Markella Pantelidou

Pavlos Panayi

Theklios Thoma

Antonia Stavraki

Xenia Argyrou

Tasos Kalogiannis

Kyriacos Yiannoukas

Christos C Petrou

Kyriacos Felekkis

Roles

Abstract

Introduction

Methods

Population

Laboratory testing

Blood collection, handling, and storage

Antibodies measurement

Statistical analysis

Results

Demographics and vaccination coverage

Table 1. Characteristics of the 702 participants.

Table 2. Vaccination coverage in terms of vaccine type and number of doses given.

Fig 1. Anti-spike IgG antibody responses.

Fig 2. Levels of IgG against SARS-CoV-2 in individuals without evidence of prior infection.

Correlation of antibody levels post-vaccination with the age of the participants

Fig 3. Correlation of anti-SARS-CoV-2 IgG levels and age of participants without evidence of prior infection who had received at least one dose of a vaccine.

Comparison between the levels of SARS-CoV-2 antibodies elicited by SARS-CoV-2 vaccination and infection

Fig 4. Levels of anti-spike IgG across study groups.

Time course of anti-spike IgG antibodies after vaccination with one dose

Fig 5. Anti-spike IgG levels by time in individuals who received a single dose of a licensed vaccine.

Time course of anti-spike IgG antibodies after vaccination and natural infection

Fig 6. Anti-spike IgG levels by time in different groups.

Discussion

Conclusions

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Tian Wang

Roles

Author response to Decision Letter 0

Decision Letter 1

Tian Wang

Roles

Author response to Decision Letter 1

Decision Letter 2

Tian Wang

Roles

Acceptance letter

Tian Wang

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases